Responding to the threat of emergent infectious diseases

Klaus Schwamborn
Valneva SE, France

Emerging and re-emerging infectious diseases are a significant and growing threat to life and health of millions of people around the world with recent outbreaks such as Ebola and Zika claiming thousands of lives and costing billions of dollars. Vaccines contributing to outbreak prevention and treatment are the most effective solution to save lives and reduce associated costs. In order to respond quickly and appropriately to current and upcoming emergent infectious diseases Valneva SE has established a vaccine platform that allows the development of highly efficient vaccines for a variety of different viruses in particular for mosquito-borne infectious diseases. Case studies of Zika, chikungunya and yellow fever will be presented demonstrating that the combination of cell culture platforms and other technologies has led to the generation of novel vaccine candidates that are ready to enter clinical development. In this context a vector based NDV approach will also be discussed.

Biography

Klaus Schwamborn is currently the Vice President in the Department of Vaccine Research at Valneva SE and serves as the Director of BlinK Biomedical SAS, France. He is involved in finding innovative approaches and technologies to generate novel vaccine candidates. He has also held international positions at Pepscan Therapeutics and Celgene. He has broad experience in drug discovery and research in infectious diseases and oncology including the areas of therapeutics antibodies and peptide based biologics. He received his PhD from the University of Göttingen and completed his Post-doctoral studies from the Institute Pasteur, Paris.

klaus.schwamborn@valneva.com